In the BioHarmony Drug Report Database

"Preview" Icon

Maraviroc

Selzentry, Celsentri (maraviroc) is a small molecule pharmaceutical. Maraviroc was first approved as Selzentry on 2007-08-06. It is used to treat HIV infections in the USA. It has been approved in Europe to treat HIV infections. The pharmaceutical is active against C-C chemokine receptor type 5. In addition, it is known to target Rubredoxin. Selzentry’s patents are valid until 2022-11-25 (FDA).

 

Trade Name

 

Celsentri
 

Common Name

 

maraviroc
 

ChEMBL ID

 

CHEMBL1201187
 

Indication

 

hiv infections
 

Drug Class

 

Antivirals; CCR5 antagonists

Image (chem structure or protein)

Maraviroc structure rendering